PACT MEA stands for Prevalence and Clinical Management of Atherosclerotic

Cardiovascular Disease in Patients with Type 2 Diabetes in the Middle East and

Africa. The PACT-MEA study provides one of the first and most comprehensive

assessments of CV risk in people with T2D from the Middle East and Africa

regions.

ASCVD is caused by the build-up of fats, cholesterol, and other substances in

and on the artery walls, which narrows the vessels and results in reduced blood

flow, potentially leading to events like heart attack and stroke.

ASCVD - defined as coronary heart disease (CHD), cerebrovascular disease, or

peripheral arterial disease presumed to be of atherosclerotic origin—is the

leading cause of morbidity and mortality for individuals with diabetes, yet high

quality contemporary data on the prevalence of cardiovascular risk in people

with T2D are lacking in the Middle East and Africa regions1

As mentioned by Dr. Hesham El Hefnawy Professor of diabetes and

endocrinology, Ex-Dean of the National Institute of Diabetes, and Head of

the national non-communicable diseases committee “The growing trend of

diabetes in the Middle East and North Africa region is alarming and the

International Diabetes Federation (IDF) predicts that the number of cases will

increase to 136 million by 2045 People with diabetes have a 2-to-4-fold higher risk

of CVD than those without diabetes.“

Dr. Hesham also added: “The purpose of this non-interventional study was to

investigate the epidemiology and clinical management of established ASCVD/ high

ASCVD risk in patients with T2D across selected countries in the Middle East and

Africa in a real-world setting”

Professor Hanan Setouhy, Professor of endocrinology and diabetes,

Mansoura University added:

“PACT-MEA is a noninterventional, cross-sectional, observational study conducted at

55 centers in 7 countries (Bahrain, Egypt, Jordan, Kuwait, Qatar, South Africa,

and the United Arab Emirates)”

“The overall study sample included 3726 individuals with 550 patients from Egypt,

The mean age was 58 years, with fair representation of male (53%) and female

(47%) population”

Professor Samir Helmy Assaad Khalil, Professor of Diabetes, Lipidology

and Metabolism, Alexandria Faculty of Medicine, Alexandria University

mentioned that:

"The weighted prevalence of ASCVD in this study was 20.9%; meaning that 1 in 5

patients with type 2 diabetes has ASCVD. The study also showed that 99.3% of

patients with T2D have high/very high ASCVD risk (as defined by the European

Society of Cardiology Guidelines 2021) across the 7 Middle East and Africa

countries.”

Professor Samir further added “And despite the high percentage of patients at

high/very high risk of ASCVD, a small percentage of patients used anti-diabetic

medications with cardiovascular benefits, and none of the participant patients

achieved all guideline-recommended treatment targets.”

Dr. Ayman Hassan, VP and GM of Novo Nordisk Egypt stated that Novo Nordisk is committed to innovation in research and development, with a focus on developing new medications and treatments for a wide range of health conditions including Diabetes, Obesity, NASH and others. The company has invested heavily in R&D, developing a pipeline of innovative medicines, with the goal of improving patient’s outcomes and transforming the healthcare industry.

EDA Approval: WF0025A8566_122023